Description

Limaprost is a synthetic prostaglandin E1 (PGE1) analogue, a high-purity active pharmaceutical ingredient (API) with significant therapeutic potential. Its primary value lies in its potent vasodilatory and antiplatelet aggregation properties, making it a critical component for advanced pharmaceutical formulations. This compound is essential for manufacturers in the pharmaceutical industry, particularly those developing treatments for peripheral vascular disorders and certain neurological conditions. The product is supplied as Limaprost CAS NO 88852-12-4, meeting stringent quality standards for global pharmaceutical applications.

Application

• Pharmaceutical API: Primary use as the active ingredient in prescription medications for the treatment of thromboangiitis obliterans (Buerger's disease) and other ischemic peripheral circulatory disorders.
• Neurological Therapeutics: Key component in formulations targeting neuropathic pain and investigated for potential use in spinal stenosis and other nerve compression-related conditions.
• Vasodilator Formulations: Used in the development of drugs designed to improve blood flow by dilating arteries and inhibiting platelet clumping.
• Clinical Research & Development: Serves as a reference standard and building block in preclinical and clinical studies for new cardiovascular and neurological drugs.
• Advanced Drug Delivery Systems: Incorporated into controlled-release tablets and other sophisticated dosage forms to ensure stable and effective delivery.

Basic Information

Product Name	Limaprost
CAS No.	88852-12-4
Molecular Formula	C22H36O5
Molecular Weight	380.52 g/mol
Synonyms	OP-1206; α-Lipoic acid derivative (PGE1 analogue); Prostaglandin E1 analogue; Limaprost alfadex (when complexed); (5Z,13E)-(9S,11R,15R)-9,11,15-Trihydroxyprosta-5,13-dien-1-oic acid; 17S,20-Dimethyl-trans-δ2-PGE1; Limaprostum [Latin]; Contact for details on additional trade names.
EINECS	Contact for details

Quality Control

Our Limaprost is manufactured under strict quality management systems, ensuring it meets the high-purity requirements for pharmaceutical use. Each batch undergoes comprehensive analytical testing, including identity confirmation, potency assay, and rigorous impurity profiling to comply with ICH guidelines. A Certificate of Analysis (COA) documenting purity (typically ≥98% by HPLC), related substances, residual solvents, and other critical parameters is provided with every shipment to guarantee traceability and consistency.

Storage

Preserve in a tightly closed container, protected from light. Store under an inert atmosphere (e.g., nitrogen) at a controlled room temperature of 15-25°C (59-77°F) or as specified on the label. The product is light-sensitive and easily oxidized; prolonged exposure to air, light, or elevated temperatures should be avoided to maintain stability and potency.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference standard
Identification (HPLC)	Retention time matches reference
Assay (HPLC)	98.0% - 102.0% (on anhydrous basis)
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 0.5%
Water Content (KF)	≤ 1.0%
Residual Solvents (GC)	Complies with ICH Q3C
Heavy Metals	≤ 20 ppm
Specific Rotation	Contact for details

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.